AbeonaBio

Welcome, @keithgoldan to our Board of Directors! “I am excited to join the Board of Directors at Abeona at this important time in the organization’s growth as commercial momentum continues to build for its first US launch,” said Mr. Goldan. Read more: bit.ly/4csA37E

New in NY: We have announced a Qualified Treatment Center providing access to our first-of-its-kind, FDA-approved gene therapy for the #RDEB community. Read more: bit.ly/AbeonaNYCQTC #MedEd

#NEWS: Abeona Therapeutics shared our Q4 and FY 2025 financial results and corporate updates. Listen to the highlights: bit.ly/475GmuY #Investors #Earnings $ABEO

Abeona Therapeutics is live at @LeerinkPartners Global Healthcare Conference 2026! Tune in to the fireside chat: bit.ly/4ukx8F1 $ABEO

This #InternationalWomensDay, we celebrate the incredible women whose leadership and dedication drive our mission forward. Thank you for making a meaningful impact every day. #IWD2026 #TeamAbeona

Today, we celebrate the employees who make our mission possible. Thank you for advancing cell and gene therapies for people impacted by serious diseases. #EmployeeAppreciationDay #TeamAbeona

On Tuesday, March 17, join our conference call where we will discuss our Q4 and full year 2025 financial results and corporate progress. Learn more: bit.ly/3MDymug $ABEO

On #RareDiseaseDay, we stand with the rare disease community and amplify awareness for #RDEB, a rare and devastating genetic skin disorder where people suffer from large chronic wounds. We support you and are committed to advocating alongside you.

During Rare Disease Month, join us in shining a light on #RDEB, a rare and debilitating genetic skin disease where people suffer from large and chronic wounds. Together, we can educate, raise awareness and help drive progress and change. #MedEd

Wishing you peace and joy this holiday season. At Abeona Therapeutics, we remain committed to putting patients first through integrity, determination, trust and innovation. Thank you for your continued support and joining us on this journey. #HappyHolidays!

We are thrilled to announce the activation of a new Qualified Treatment Center in Texas, expanding access to our FDA-approved autologous, gene therapy for patients living with recessive dystrophic epidermolysis bullosa (#RDEB). Read more: bit.ly/AbeonaNewQTCTe… #MedEd

Today, Abeona Therapeutics is proud to bring our cell-based gene therapy to patients. “Treating our first patient is a proud moment for Abeona and a testament to the tireless resolve of our team.” — Vish Seshadri, CEO Learn more: bit.ly/AbeonaFirstPat… #MedEd

This holiday season, we reflect on the many things we are grateful for.   For our community members who lead with integrity and determination, our dedicated employees who make our mission possible and the patients we strive to help.   #HappyThanksgiving from all of us.💙💚

What is the value of providing a gene therapy to help people suffering from recessive dystrophic epidermolysis bullosa? Abeona Therapeutics SVP, Chief Commercial Officer and Head of Business Development Madhav Vasanthavada, Ph.D., M.B.A., answers the question.

Earlier this week, Abeona Therapeutics reported our third quarter 2025 financial results and corporate updates. Listen to the highlights: bit.ly/Abeona3Q2025Up… #Investor #Earnings

Abeona Therapeutics has been recognized for our dedication to innovation, integrity, determination, trust and putting patients first.   We are honored to have been recognized and celebrated by our employees as a 2025 Northeast Ohio Top Workplaces winner.

During the 2025 #debraGala, we received the “Partners in Progress Award – Approved Treatment” which celebrates our commitment to advancing treatments for #epidermolysisbullosa (EB). Thank you, @debraOfAmerica, for this incredible honor!

We stand with the epidermolysis bullosa (EB) community in recognizing and raising awareness for #EBAwarenessWeek. Join us in supporting the cause and help us bring visibility to this rare and painful genetic disorder. #EBWeek #WeFightEB

We’re excited to announce the appointment of James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President, Head of Clinical Development & Medical Affairs at Abeona Therapeutics. Read more 👉 bit.ly/AbeonaJamesGow… #Biotech #Innovation #Leadership

We are proud to share that one of our gene therapy candidates has been selected for the @US_FDA Rare Disease Endpoint Advancement (RDEA) Pilot Program. Discover what this means for Abeona: bit.ly/AbeonaFDARDEAS… #meded